Teva and Alvotech stocks jump on FDA approval of SELARSDI

Published 05/05/2025, 13:42
© Reuters

Investing.com -- Shares of Teva Pharmaceutical (TADAWUL:2070) Industries Ltd ADR (NYSE:TEVA) surged 6.2% while Alvotech SA (NASDAQ:ALVO) climbed 3.5% in premarket trading today, following the U.S. Food and Drug Administration’s (FDA) approval of SELARSDI™ as interchangeable with the reference biologic Stelara®. This approval, effective from April 30, 2025, covers all presentations matching the reference product.

SELARSDI, developed in partnership by Teva and Alvotech, is indicated for the treatment of various immune-mediated and inflammatory conditions, including moderate to severe plaque psoriasis, active psoriatic arthritis in adults and children over six, and moderately to severely active Crohn’s disease and ulcerative colitis in adults. The FDA’s designation of interchangeability implies that SELARSDI can be substituted for the reference drug without the intervention of the healthcare provider who prescribed the reference product.

Teva’s Senior Vice President, U.S. Biosimilars, Thomas Rainey, remarked on the significance of this development, highlighting the company’s expanding biosimilars portfolio and its potential to drive growth as Teva embarks on the next phase of its strategy. Anil Okay, Chief Commercial Officer for Alvotech, also emphasized the importance of interchangeability in increasing patient access to affordable treatments and reducing healthcare costs.

The approval of SELARSDI follows the strategic partnership between Teva and Alvotech, formed in August 2020, which focuses on the commercialization of five biosimilar product candidates. This partnership was extended in July 2023 to include two additional biosimilars. To date, two biosimilars from this partnership have been approved by the FDA with interchangeability status, with SELARSDI being the latest.

Furthermore, the FDA is currently reviewing Biologics License Applications for three more biosimilar candidates from Alvotech, with expected approval dates in the fourth quarter of 2025. These developments underscore the companies’ commitment to expanding their biosimilar offerings and their potential impact on the pharmaceutical market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.